The global sennosides market is expected to be worth USD 359.5 million in 2023. The demand for sennosides is likely to grow at 4.3% CAGR between 2023 and 2033, totaling a market valuation of USD 548.5 million by 2033.
Based on drug type, the sennosides segment leads the global sennosides market with a share of around 71.7%. This can be attributed to the easy availability and low cost of sennosides and the rising consumption of sennosides for treating various diseases.
Emerging trends reveal that a surge in cases of constipation worldwide will play a key role in boosting sennosides sales during the forecast period. Constipation is the most common clinical ailment that affects a significant portion of the population. It can result from drug overuse. Hence products containing natural extracts have been used for their treatment for many years.
Sennosides is one such medicine that is frequently used to treat constipation. It is made from a leaf of the plant Senna Alexandrina and is used as a temporary treatment to relieve constipation.
The wide use of sennosides to clean up the intestine before a colonoscopy also pushes the demand for sennosides. These stimulating laxatives are used to maintain water in the intestines and to promote intestinal movement. Hence, these are highly in demand to treat this condition.
| Attribute | Key Statistics |
|---|---|
| Estimated Market Value (2023) | USD 359.5 million |
| Projected Market Value (2033) | USD 548.5 million |
| Value-based CAGR (2023 to 2033) | 4.3% |
| Market Share of Top 5 Countries | 56.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of sennosides grew at a CAGR of 3.9% between 2018 and 2022. However, with the increasing prevalence of diseases like constipation and rising health awareness among people, the overall sales of sennosides are slated to rise at a steady CAGR of 4.3% between 2023 and 2033.
The rising preference for herbal extracts worldwide is driving the market for sennosides. Over the years consumer preference towards organic herbal extract products has increased significantly over the years due to the minimal or no side effects of herbal products or medications, unlike allopathy drugs. As a result, they are being increasingly used for both medicinal purposes as well as dietary supplements.
Sennosides, one such herbal product, are used for treating constipation or gut cleaning by most of the target population. Market players are coming up with new flavors in these products to mask the naturally unpleasant taste of the product. This is expected to boost the sales of the sennosides during the forecast period.
Similarly, the rapid shift towards organic products has ignited the demand for plant-based nutrition worldwide. The growing concept of the nutrition gap due to rising cases of chronic degenerative diseases and a sedentary lifestyle hindering the ability to consume enough micronutrients has grown the preference for nutraceuticals and herbal medications. This is positively impacting the demand for sennosides.
Humans' sedentary lifestyle and unhealthy dietary patterns have led to increased health conditions. Treatment for these health conditions might include a heavy dosage of certain medications or the inclusion of polypharmacy.
Conditions requiring certain medications like sedatives, antidepressants, opioid pain medications, and medications to lower blood pressure might lead to infrequent bowel movements or constipation. Though intermittent constipation is frequent, some people also have chronic constipation, which might hinder their daily activity. Thus, the increasing prevalence and burden of functional gastrointestinal disorders will likely propel the sennosides market's growth over the next decade.
Escalating Academic Research to Explore Potential Effects of Sennosides Aiding Sennosides Market Growth
According to the National Science Board, academic institutions have historically carried out roughly 50% of all United States basic research and 10% to 15% of all R&D, with an investment of USD 83.7 billion in 2019 in the United States. Moreover, half of all financing for academic R&D in 2019 came from the federal government. Academic research is comparatively less expensive than research done in the laboratories of pharmaceutical companies.
Also, the results vary less when it comes to the development and research of pharmaceutical products, making it one of the preferred options for research and evaluation of the sennosides. This helps in generating more profits propelling the growth of the sennosides market.
Additionally, there has been increasing research on sennosides to treat AIDS caused by HIV. Growing cases of HIV will, hence, boost the growth of the sennosides market. According to the World Health Organization, 38.4 million people were living with HIV/AIDS worldwide in 2023. During the foreseeable years, this is expected to provide lucrative opportunities for growth in the overall sennosides market.
Principal Consultant
Sennosides are a type of stimulant laxative and are used to improve bowel movement. Improper consumption of these laxatives can lead to serious health conditions like abdominal pain or discomfort, cramps, diarrhea, nausea, electrolyte abnormalities, and kidney inflammation. Sennosides are also known to have a severe interaction with other drugs. This is hindering the sennosides market growth.
Furthermore, consumers still have skepticism regarding the health benefits of nutraceutical products. The two biggest issues preventing customers from accepting nutraceutical items are synthetic sourcing and questionable health claims.
These factors cumulatively propose a negative effect on the developmental growth of the sennosides market.
Surge in Numerous Diseases Creating Sales Prospects for Sennosides in China Market
China held approximately 56.0% share in the East Asia market in 2023 and is projected to expand at a CAGR of 4.2% during the forecast period (2023 to 2033).
The increasing burden of chronic diseases in China is creating the need for a high medication dosage for treatment. For instance, according to the Global Burden Disease Study of 2019, hypertensive heart disease (HHD) accounted for 7.9 million cases and 320,089 deaths in China. To prevent and treat these medical conditions, people consume numerous medicines.
However, these medications cause gastrointestinal issues affecting normal bowel movements, leading to constipation. This has resulted in shifting to herbal products like sennosides to treat constipation. Driven by this, demand for sennosides in China is set to rise steadily over the next ten years.
Rising Prevalence of Constipation Boosting Sennosides Sales in the United States
The United States dominated the North American sennosides market with a total market share of about 32.5% in 2023, and this trend is likely to continue during the forecast period.
High consumption of a low-fiber diet that includes milk, meat, and cheese has elevated the problem of constipation and irregular bowel movement among the United States population. Intake of dietary fiber among people in the United States has decreased, with an average intake of 15 grams per day, almost half the recommended amount giving rise to constipation issues.
The American Heart Association Eating Plan advises consuming a range of food sources high in fiber. Thus, increasing the incidence of constipation due to low fiber consumption will continue to push demand for sennosides during the forecast period.
Rapid Shift Towards Herbal Medicines Triggering Sennosides Market Growth in Germany
As per FMI, Germany is set to exhibit a CAGR of nearly 3.9% during the forecast period, owing to the rapid shift towards herbal medicines, a surge in chronic diseases like constipation, and rising health awareness among people.
In recent years, increased herbal medicine usage in the German healthcare system has boosted the demand for sennosides. According to the BMC Health Services Research of 2019, it was found that the Germans largely used herbal medicines due to the safety and preference for self-medication or OTC medications.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand to Remain High for Sennosides in the Global Market
As per FMI, the sennosides segment held the largest share of about 71.7% in the global sennosides market in 2023, and it is expected to grow at a CAGR of 4.2% throughout the forecast period. This is attributed to the low cost and easy availability of sennosides in drug stores. Also, the gastroprotective abilities of sennoside A and sennoside B are the reason for the preference for sennosides over mixed laxatives.
End Users Prefer Sennoside Tablets Over Other Dosage Types
The tablet segment held a revenue share of 67.7% in 2023 and is expected to grow at 4.2% during the forecast period. This is attributed to the easy administration of the tablet form of dosage. Additionally, the tablet dosage has a higher shelf life and is stable and hence preferred by most of the population.
Sennosides Remains Highly Sought After Treatment for Constipation
The constipation segment will continue to dominate the global sennosides market, accounting for around 36.3% revenue share in 2023. This is attributable to the rising prevalence of constipation due to certain medications and including junk and low-fiber food in the diet.
People usually opt for medications like sennosides to treat constipation because of their safe and effective nature.
Retail Pharmacies to Witness Highest Sennosides Sales in 2023 and Beyond
As per FMI's latest analysis, retail pharmacies held the highest market share value of 34.6% in 2023, and this number is likely to surge further over the forthcoming decade. The easy availability of sennosides at lower prices and growing consumer preference for purchasing sennosides from retail pharmacies are triggering the growth of this segment.
Manufacturers of sennosides are undergoing partnerships, collaborations, and acquisitions to increase their footprint in the market. Additionally, they are innovating their products to increase their sales. For instance,
Similarly, companies like Aviro Health L.P. are expanding their sennosides business by launching brands like Senokot. For instance, the company recently launched two new Senokot dietary supplement products.
Furthermore, startups like MEETSUPPLEMENT (founded in 2020) are entering the sennosides space to grab emerging opportunities and expand their businesses.
| Attribute | Details |
|---|---|
| Estimated Market Size (2023) | USD 359.5 million |
| Projected Market Size (2033) | USD 548.5 million |
| Anticipated Growth Rate (2023 to 2033) | 4.3% CAGR |
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania and Middle East & Africa |
| Key Countries Covered | Australia, New Zealand, India, Indonesia, Malaysia, Thailand, Rest of South Asia, China, Japan, South Korea, Germany, Italy, France, UK, Spain, BENELUX, Nordic Countries, Russia, Rest of Europe, Mexico, Brazil, Argentina, Rest of Latin America, US, Canada, GCC, Turkey, South Africa, Rest of MEA |
| Key Market Segments Covered | Drug Type, Dosage Type, Application, Distribution Channel, and Region |
| Key Companies Profiled | Avrio Health L.P; Vital Laboratories; Pharmaceutical Associates, Inc; Boyd Pharmaceuticals Inc.; Bioprex Lab; Roha Arzneimittel Gmbh; Numark Laboratories, Inc; Amvilab Llc; Shashi Phytochemical; Perrigo (Herron Pharmaceuticals); Alchem International; Time-Cap Labs Inc; EarthBorn Elements; Kothari Phytochemicals; Genexa Inc.; Abdi Ibrahim Pharmaceuticals Industry; SafeCore Health LLC.; Pharbest Pharmaceuticals; Santa Farma Ilaç Sanayii A.S. Borucicek Sok.; Gericare Pharmaceuticals |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The market in 2023 is valued at USD 359.5 million.
The market rose at a 3.9% CAGR from 2018 to 2022.
The market will register a 4.3% CAGR until 2033.
By 2033, the market will reach USD 548.5 million.
China will hold a 56.0% share in the East Asia market in 2023.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Sennosides 5.2. Mixed 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Type 6.1. Tablet 6.1.1. Chewables 6.1.2. Film-coated 6.2. Liquid 6.3. Powders 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. IBS 7.2. Hemorrhoids 7.3. Weight Loss/ Dietary Supplements 7.4. Constipation 7.5. Anti-Inflammatory 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Hyper Market 8.4. Online Sales 8.5. Drug Stores 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. South Asia and Pacific 9.6. East Asia 9.7. Middle East and Africa 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Avrio Health L.P 19.2. Vital Laboratories 19.3. Pharmaceutical Associates, Inc 19.4. Boyd Pharmaceuticals Inc. 19.5. Bioprex Lab 19.6. Roha Arzneimittel Gmbh 19.7. Numark Laboratories, Inc 19.8. Amvilab Llc 19.9. Shashi Phytochemical 19.10. Perrigo (Herron Pharmaceuticals) 19.11. Alchem International 19.12. Time-Cap Labs Inc 19.13. EarthBorn Elements 19.14. Kothari Phytochemicals 19.15. Genexa Inc. 19.16. Abdi Ibrahim Pharmaceuticals Industry 19.17. SafeCore Health LLC. 19.18. Pharbest Pharmaceuticals 19.19. Santa Farma Ilaç Sanayii A.S. Borucicek Sok. 19.20. Gericare Pharmaceuticals 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Sennosides Market
